Mark Pegram, MDEnriched profile
Susy Yuan-Huey Hung Endowed Professor of Medical Oncology; Associate Director of Clinical Research, Stanford Comprehensive Cancer Institute; Associate Dean for Clinical Research Quality, Stanford School of Medicine; Medical Director, Stanford Clinical Translational Research Unit · Stanford University
Overview
Updated 14 Jul 2026
Mark D. Pegram, MD, is Susy Yuan-Huey Hung Endowed Professor of Medical Oncology at Stanford University School of Medicine, Department of Medicine - Oncology (Stanford Women's Cancer Center / Stanford Comprehensive Cancer Institute). The public record shows 421 publications with 41,838 citations (h-index 67), centered on HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Cancer Treatment and Pharmacology. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2016–2020).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: HER2/EGFR in Cancer Research
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 15 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 169.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
Sponsor: Stanford University
InvestigatorPhase 1/PHASE2TerminatedNCT01928030 - Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Sponsor: Stanford University
InvestigatorPhase 2TerminatedNCT00481845 - T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Sponsor: Jonsson Comprehensive Cancer Center
InvestigatorCompletedNCT00433407
Industry payments
Updated 14 Jul 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202519 payments$19,170openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20259 payments
- PFIZER INC.Program year20253 payments
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2016–2020 per NIH RePORTER. The latest:
Congress activity
Updated 14 Jul 2026
122 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract LB169: Establishment of patient-derived organoid (PDO) from single cell-originated core-needle biopsied (CNB) samples of breast cancer
AACR Annual Meeting
AACR2025Co-authorLate-breaking - Predictors of overall survival in patients with brain metastases from HER2+ breast cancer.
ASCO Annual Meeting
ASCO2025Co-author - Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer3,794 citations2012
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
900 Blake Wilbur Drive, MC 5348, Palo Alto, CA 94304
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Editorial board member
Breast Cancer Research and Treatment (Springer Nature)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →link.springer.com ↗ - First Director
Breast Cancer Oncology Program, Stanford Women's Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Secondary affiliationsappointments beyond the home institution
- Member
Bio-X, Stanford University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biox.stanford.edu ↗ - Member
Stanford Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Scientific Advisory Board member
Beyond Cancer (appointed alongside Frederick M. Dirbas, MD, per sponsored research agreement with Stanford)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →beyondcancer.com ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mashupmd.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/mark-pegram-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Instagram
instagram.com/p/DQHaOEYjsea
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/lieszl_mark-pegram-md-reviews-utility-of-breast-activity-6950965806847463425-gbAY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
mashupmd.com/podcast-mark-pegram-md-stanfordhealth-stanfordcanc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mashupmd.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University
- 1,067
- publications
- 113
- h-index
- 7
- trials
Crystal Mackall, MD
Stanford University
- 333
- publications
- 75
- h-index
- 9
- trials
David Maron, MD
Stanford University
- 455
- publications
- 67
- h-index
- 4
- trials
Robert Shafer, MD
Stanford University
- 377
- publications
- 86
- h-index
- 2
- trials